Arvinas, Inc. (NASDAQ:ARVN) Stock Has Consensus Price Target of $14.55

Arvinas, Inc. (NASDAQ:ARVN) has been assigned a consensus recommendation of “Hold” from the ten brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $14.55.

ARVN has been the subject of several analyst reports. Weiss Ratings raised shares of Arvinas from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday. Morgan Stanley set a $10.00 price target on shares of Arvinas in a research note on Monday, August 10th. Wall Street Zen upgraded shares of Arvinas from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. BTIG Research reissued a “buy” rating and issued a $18.00 price objective on shares of Arvinas in a research report on Tuesday, August 4th. Finally, Wells Fargo & Company reissued an “equal weight” rating and issued a $11.00 price objective (down from $15.00) on shares of Arvinas in a research report on Tuesday, August 4th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC purchased a new position in shares of Arvinas during the 2nd quarter worth $48,000. Quantbot Technologies LP purchased a new stake in shares of Arvinas in the second quarter valued at $85,000. Corient Private Wealth LP acquired a new position in Arvinas in the second quarter valued at $95,000. Pale Fire Capital SE acquired a new position in Arvinas in the second quarter valued at $99,000. Finally, Canada Pension Plan Investment Board purchased a new position in Arvinas during the second quarter worth about $112,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Stock Performance

Shares of NASDAQ:ARVN opened at $7.64 on Thursday. The business’s fifty day moving average price is $8.57 and its two-hundred day moving average price is $8.92. The stock has a market cap of $492.93 million, a PE ratio of 76.41 and a beta of 1.80. Arvinas has a one year low of $6.97 and a one year high of $14.51.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Tuesday, August 4th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $2.95. The company had revenue of $249.70 million during the quarter, compared to analysts’ expectations of $60.71 million. Arvinas had a return on equity of 1.91% and a net margin of 2.94%. The business’s revenue for the quarter was up 1014.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.84) earnings per share. As a group, equities research analysts predict that Arvinas will post 0.05 earnings per share for the current fiscal year.

About Arvinas

Arvinas, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary PROTAC targeted protein degradation platform to design small-molecule therapies intended to direct unwanted proteins to the cell’s natural disposal system.

Arvinas’ programs have primarily focused on oncology. Its lead investigational program, vepdegestrant (ARV-471), is an oral estrogen receptor degrader being developed for patients with estrogen receptor-positive, HER2-negative breast cancer.